Mutant Unc93b1 Protein Modulates TLR7 and TLR8 Signaling
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods fail to effectively modulate the trafficking and signaling of Toll-Like Receptor 7 (TLR7) and Toll-Like Receptor 8 (TLR8), which are crucial for immune responses but can contribute to autoimmune disorders and inadequate antiviral immunity.
Innovation Solution
A mutant Unc93b1 protein with specific amino acid mutations is used to modulate the trafficking and signaling of TLR7 and TLR8, either increasing or decreasing their activity depending on the therapeutic need, by administering the protein or modifying the Unc93b1 gene to express these mutations.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If TLR7 and TLR8 activity is enhanced to improve antiviral immunity, then immune response effectiveness is improved, but risk of autoimmune disorders increases
Solution Approach 1:
The patent applies parameter changes by introducing specific amino acid mutations in Unc93b1 protein (such as D34A, Y99A, Y154A, K197A, H412R, and deletions like PKP(530,531,532)) to precisely modulate TLR7 and TLR8 trafficking and signaling parameters. These mutations enable selective enhancement of antiviral immunity while suppressing autoimmune responses by altering the biochemical parameters of receptor trafficking without changing the overall system architecture.
Solution Approach 2:
The patent implements local quality by creating heterogeneity in Unc93b1 protein function through site-specific mutations. Different mutations produce different local effects on specific TLR isoforms (TLR7 vs TLR8) while leaving other TLR pathways relatively unaffected. This allows selective modulation of TLR7/8 activity in specific cellular contexts to achieve enhanced antiviral protection without triggering systemic autoimmune responses.
2Object-affected harmful factors
If TLR7 and TLR8 activity is suppressed to treat autoimmune disorders, then autoimmune symptoms are reduced, but antiviral immunity becomes inadequate
Solution Approach 1:
The patent uses parameter changes by selecting specific Unc93b1 mutations that tilt the signaling parameter balance toward anti-inflammatory outcomes. Mutations such as D34A and Y99A specifically reduce TLR7-mediated autoimmune signaling while preserving baseline antiviral surveillance capacity. This enables treatment of autoimmune disorders while maintaining sufficient antiviral immunity through precise parameter adjustment rather than complete suppression.
Solution Approach 2:
The patent applies dynamics by creating a mutable, adaptable immune system through Unc93b1 mutations that can dynamically respond to different pathogenic threats. The mutated Unc93b1 protein enables the system to shift its signaling parameters in response to contextual cues, providing robust antiviral protection when needed while suppressing autoimmune inflammation under different conditions, thus achieving dynamic balance between protection and tolerance.
3Reliability
If mutant Unc93b1 proteins are administered to modulate TLR activity, then therapeutic effect is achieved, but protein structure complexity increases
Solution Approach 1:
The patent applies parameter changes by introducing minimal, targeted amino acid substitutions and deletions in the Unc93b1 protein sequence rather than making extensive structural modifications. These focused changes (such as single amino acid substitutions at positions 34, 99, 154, 197, 412, or small deletions like PKP(530,531,532)) achieve significant therapeutic effects on TLR7 and TLR8 modulation while maintaining relatively simple protein structure and facilitating ease of production and clinical translation.
Data Source
AI summary
Disclosed herein are Unc93bl mutations that modulated the trafficking and/or signaling of TLR7, and compositions and methods of using thereof.